DZ1850A1 - Formulation nouvelle comprenant un complexe de paroxétine et d'amberlite irp 88. - Google Patents

Formulation nouvelle comprenant un complexe de paroxétine et d'amberlite irp 88.

Info

Publication number
DZ1850A1
DZ1850A1 DZ950010A DZ950010A DZ1850A1 DZ 1850 A1 DZ1850 A1 DZ 1850A1 DZ 950010 A DZ950010 A DZ 950010A DZ 950010 A DZ950010 A DZ 950010A DZ 1850 A1 DZ1850 A1 DZ 1850A1
Authority
DZ
Algeria
Prior art keywords
paroxetine
complex
new formulation
amberlite irp
irp
Prior art date
Application number
DZ950010A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DZ1850A1 publication Critical patent/DZ1850A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
DZ950010A 1994-02-03 1995-02-01 Formulation nouvelle comprenant un complexe de paroxétine et d'amberlite irp 88. DZ1850A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9402029A GB9402029D0 (en) 1994-02-03 1994-02-03 Novel formulation

Publications (1)

Publication Number Publication Date
DZ1850A1 true DZ1850A1 (fr) 2002-02-17

Family

ID=10749765

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ950010A DZ1850A1 (fr) 1994-02-03 1995-02-01 Formulation nouvelle comprenant un complexe de paroxétine et d'amberlite irp 88.

Country Status (33)

Country Link
US (1) US5811436A (fr)
EP (1) EP0742715B1 (fr)
JP (1) JP4445590B2 (fr)
CN (1) CN1074922C (fr)
AP (2) AP611A (fr)
AT (1) ATE178489T1 (fr)
AU (1) AU682091B2 (fr)
BG (1) BG62843B1 (fr)
BR (1) BR9507055A (fr)
CA (1) CA2182593A1 (fr)
CZ (1) CZ285128B6 (fr)
DE (1) DE69508924T2 (fr)
DK (1) DK0742715T3 (fr)
DZ (1) DZ1850A1 (fr)
ES (1) ES2129806T3 (fr)
FI (1) FI118205B (fr)
GB (1) GB9402029D0 (fr)
GR (1) GR3030131T3 (fr)
HU (1) HUT75941A (fr)
IL (1) IL112521A (fr)
MA (1) MA23441A1 (fr)
MX (1) MX9603203A (fr)
MY (1) MY113036A (fr)
NO (1) NO307954B1 (fr)
NZ (1) NZ278891A (fr)
OA (1) OA10446A (fr)
PL (1) PL178331B1 (fr)
RO (1) RO116342B1 (fr)
RU (1) RU2136281C1 (fr)
SK (1) SK281214B6 (fr)
TW (1) TW436296B (fr)
WO (1) WO1995020964A1 (fr)
ZA (1) ZA95776B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
CZ295301B6 (cs) 1997-06-10 2005-07-13 Synthon B. V. Deriváty 4-fenylpiperidinu, způsob jejich přípravy, jejich použití a lék je obsahující
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6660298B1 (en) * 2000-07-27 2003-12-09 Pentech Pharmaceuticals, Inc. Paroxetine tablets and capsules
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
DE60232290D1 (de) * 2001-04-09 2009-06-25 Rohm & Haas Kontrollierte Auflösung von Wirkstoffen
US20020176842A1 (en) * 2001-04-09 2002-11-28 Lyn Hughes Extended release of active ingredients
US6906206B2 (en) * 2001-04-30 2005-06-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
ATE321530T1 (de) * 2001-08-09 2006-04-15 Smithkline Beecham Plc Zusammensetzung enthaltend paroxetin und ein pharmazeutisch verträgliches salz von glycyrrhizinsäure
GB0119467D0 (en) * 2001-08-09 2001-10-03 Smithkline Beecham Plc Novel compound
US6939877B2 (en) * 2002-09-12 2005-09-06 Wyeth Antidepressant piperidine derivatives of heterocycle-fused benzodioxans
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
WO2006018318A1 (fr) * 2004-08-18 2006-02-23 Synthon B.V. Compositions liquides de paroxetine
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
KR100672184B1 (ko) * 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
AU2006315684A1 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
CN102430122A (zh) * 2005-12-13 2012-05-02 量子高科(北京)研究院有限公司 盐酸氟西汀口腔崩解片及其制备方法
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20100273822A1 (en) * 2009-04-22 2010-10-28 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins
US8758779B2 (en) 2009-06-25 2014-06-24 Wockhardt Ltd. Pharmaceutical composition of duloxetine
US8187617B2 (en) * 2009-09-11 2012-05-29 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments
ES2588008T3 (es) 2010-05-19 2016-10-28 Astellas Pharma Inc. Composición farmacéutica que contiene solifenacina
CN104027306A (zh) * 2014-06-25 2014-09-10 万特制药(海南)有限公司 帕罗西汀口服混悬液及其制备方法
GB201419261D0 (en) * 2014-10-29 2014-12-10 Therakind Ltd Formulations
CN104382870A (zh) * 2014-10-30 2015-03-04 万全万特制药江苏有限公司 一种含有波拉克林钾-帕罗西汀的复合物
CN106309363A (zh) * 2016-09-24 2017-01-11 万特制药(海南)有限公司 盐酸帕罗西汀口服混悬液及其制备方法
CN108926528A (zh) * 2017-05-25 2018-12-04 北京万全德众医药生物技术有限公司 含有氨磺必利树脂酸盐的口服液体组合物
ES2991429T3 (es) 2019-02-01 2024-12-03 Univ South Carolina Compuestos de piridina bicíclicos para su uso en el tratamiento del cáncer
CN113209017B (zh) * 2021-06-02 2023-06-20 上海美优制药有限公司 一种盐酸帕罗西汀混悬剂及其制备方法
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
GB2636182A (en) 2023-12-04 2025-06-11 Novumgen Ltd An orally disintegrating tablet of paroxetine and its process of preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DE3688827T2 (de) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
GB9005498D0 (en) * 1990-03-12 1990-05-09 Beecham Group Plc Composition
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.

Also Published As

Publication number Publication date
NZ278891A (en) 1998-01-26
NO307954B1 (no) 2000-06-26
PL315679A1 (en) 1996-11-25
AP611A (en) 1997-09-03
JP4445590B2 (ja) 2010-04-07
NO963244D0 (no) 1996-08-02
DK0742715T3 (da) 1999-10-18
IL112521A (en) 1999-09-22
DE69508924D1 (de) 1999-05-12
AU1536895A (en) 1995-08-21
CA2182593A1 (fr) 1995-08-10
BG62843B1 (bg) 2000-09-29
MY113036A (en) 2001-11-30
SK281214B6 (sk) 2001-01-18
CN1140411A (zh) 1997-01-15
AP536A (en) 1996-09-26
CN1074922C (zh) 2001-11-21
IL112521A0 (en) 1995-05-26
ATE178489T1 (de) 1999-04-15
HU9602151D0 (en) 1996-09-30
GB9402029D0 (en) 1994-03-30
DE69508924T2 (de) 1999-10-21
BR9507055A (pt) 1997-09-02
JPH09508402A (ja) 1997-08-26
NO963244L (no) 1996-08-02
BG100763A (bg) 1997-03-31
WO1995020964A1 (fr) 1995-08-10
CZ285128B6 (cs) 1999-05-12
MX9603203A (es) 1997-03-29
HUT75941A (en) 1997-05-28
ES2129806T3 (es) 1999-06-16
HK1012288A1 (en) 1999-07-30
FI118205B (fi) 2007-08-31
GR3030131T3 (en) 1999-07-30
US5811436A (en) 1998-09-22
TW436296B (en) 2001-05-28
EP0742715A1 (fr) 1996-11-20
MA23441A1 (fr) 1995-10-01
AP9500715A0 (en) 1995-04-30
SK100496A3 (en) 1996-12-04
CZ229396A3 (en) 1997-01-15
AU682091B2 (en) 1997-09-18
FI963051A0 (fi) 1996-08-01
EP0742715B1 (fr) 1999-04-07
AP9600839A0 (en) 1996-07-31
FI963051L (fi) 1996-08-01
RU2136281C1 (ru) 1999-09-10
PL178331B1 (pl) 2000-04-28
ZA95776B (en) 1996-08-01
RO116342B1 (ro) 2001-01-30
OA10446A (en) 2002-03-26

Similar Documents

Publication Publication Date Title
DZ1850A1 (fr) Formulation nouvelle comprenant un complexe de paroxétine et d'amberlite irp 88.
HUS1200028I1 (hu) 4"-Szubsztituált-9-dezoxo-9a-aza-9a-homoeritromicin-származékok és ezeket tartalmazó gyógyszerek
EP0708355A3 (fr) Dispositif d'affichage
MA26497A1 (fr) Nouvelle formulation pharmaceutique
LU91437I2 (fr) "dabigatran-etexilate et ses sels- particulièrement dabigatran-etexilate-mésilate (PRADAXA)"
EP0949603A4 (fr) Dispositif d'affichage
NZ329932A (en) Hypolipidemic 1,4-benzothiazepine-1,1-dioxides and pharmaceutical compositions thereof
NO953262D0 (no) Bedring av Dupuytrens sykdom
NO981388L (no) Bedring av Dupuytrens sykdom
AU3113500A (en) Compositions for treating alzheimer's disease and other amyloidoses
EP0689086A3 (fr) Dispositif d'affichage
FR2687910B1 (fr) Presentoir d'instrumentation dentaire.
PT755386E (pt) Derivado de benzamida composicoes contendo o referido derivado e sua utilizacao
FR2618072B1 (fr) Compositions pharmaceutiques et cosmetiques a base de pyridones et d'agents antibacteriens
ITRM940387A0 (it) "giunto a tampone viscoelastico anidro".
KR960038660U (ko) 브라운관의 반전이재기
FR2728455B1 (fr) Dispositif d'osteosynthese
FR2744917B1 (fr) Composition therapeutique a base d'acetaminophene
KR970019393U (ko) 브이씨알 헤드의 로타리트랜스포머 연결구조
ITMI930453A0 (it) Composizione farmaceutica avente attivita' antiasmatica
KR960024629U (ko) 롬팩을 이용한 ibm pc 전용 게임기
KR950031507U (ko) 기판의 핀위치 표시구조
FR2768984B1 (fr) Sulky d'un nouveau type
FI1618U1 (fi) Spelbraede foer spelet "Tornering"
UA851S (uk) Гра "школярик"